BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vista Partners Updates Coverage on Mast Therapeutics; Price Target $2.25


12/19/2013 10:23:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO, CA--(Marketwired - December 18, 2013) -

Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA, with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX began dosing in its pivotal Phase 3 clinical study of MST-188 (purified poloxamer 188) in sickle cell disease in May. MSTX believes that it is currently the only company with a new molecular entity in a Phase 3 clinical trial for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented interest from strategic partners, acquisition oriented suitors, and financial investors." Mr. Silver continued, "MSTX plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. The planned Phase 2 trial in ALI is scheduled to commence in the first quarter of 2014." Mr. Silver concludes, "MSTX anticipates that cash as of September 30, 2013 or $0.48/share, should be sufficient to fully fund all planned clinical trials."

To download a FREE copy of the Mast Therapeutics Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking.

Please follow Vista Partners on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about our coverage universe of companies.

Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.


Contact:
Vista Partners
877.215.4813
Email Contact



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES